SETDB1 and small cell lung carcinoma: Indeed, several studies have identified promising therapeutic targets, such as KDM5A (40), SETDB1/2 (43), or EZH2 (44), that could potentially overcome drug resistance caused by epigenetic mechanisms in SCLC or other tumors.